Erika Pietrolongo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5416327/publications.pdf

Version: 2024-02-01

46 papers 1,334 citations

331259 21 h-index 36 g-index

46 all docs

46 docs citations

46 times ranked

1836 citing authors

#	Article	IF	CITATIONS
1	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	0.8	17
2	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. Health and Quality of Life Outcomes, 2021, 19, 224.	1.0	2
3	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	0.9	17
4	Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center. Multiple Sclerosis and Related Disorders, 2020, 38, 101504.	0.9	19
5	Assessing measurement invariance of MSQOL-54 across Italian and English versions. Quality of Life Research, 2020, 29, 783-791.	1.5	4
6	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	0.7	17
7	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. Journal of the Neurological Sciences, 2020, 417, 117064.	0.3	1
8	Data of safety in a single-center alemtuzumab treated population. Data in Brief, 2020, 29, 105341.	0.5	1
9	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	0.9	O
10	Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy. PLoS ONE, 2020, 15, e0228587.	1.1	9
11	The minimal neuropsychological assessment of MS patients (MACFIMS): normative data of the Italian population. Neurological Sciences, 2020, 41, 1489-1496.	0.9	3
12	Title is missing!. , 2020, 15, e0228587.		0
13	Title is missing!. , 2020, 15, e0228587.		O
14	Title is missing!. , 2020, 15, e0228587.		0
15	Title is missing!. , 2020, 15, e0228587.		O
16	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866.	1.4	11
17	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	1.1	21
18	Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 813-815.	1.4	11

#	Article	IF	Citations
19	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	2.8	34
20	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	1.8	44
21	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	0.8	16
22	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. Frontiers in Psychology, 2017, 8, 2216.	1.1	30
23	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763.	1.5	10
24	Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. Health Expectations, 2016, 19, 437-447.	1.1	10
25	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	0.8	39
26	Role preferences in treatment decisions of MS patients in Italy. Journal of the Neurological Sciences, 2015, 357, e316.	0.3	0
27	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
28	Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. PLoS ONE, 2015, 10, e0127734.	1.1	31
29	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184.	0.7	28
30	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
31	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
32	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679.	1.1	67
33	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
34	Implementation of the  Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. Multiple Sclerosis Journal, 2014, 20, 1234-1243.	1.4	14
35	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMSâ€Trial. Health Expectations, 2014, 17, 36-48.	1.1	12
36	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	1.4	148

#	Article	IF	CITATION
37	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.3	37
38	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	3.7	140
39	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 893.	1.0	28
40	Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale. PLoS ONE, 2013, 8, e66127.	1.1	52
41	Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments. PLoS ONE, 2013, 8, e60721.	1.1	44
42	The Kurtzke EDSS rank stability increases 4â€years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	0.9	37
43	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.3	35
44	Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study. International Journal of Clinical Practice, 2012, 66, 504-514.	0.8	17
45	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	1.1	35
46	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. Multiple Sclerosis Journal, 2010, 16, 1237-1247.	1.4	27